Moreover, results of keynote 024 and 042 supports the use of pembrolizumab monotherapy as first line treatment for PD-L1 positive NSCLC patients, especially for high expression population [19, 20]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.